PENUMBRA INC (PEN) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:PEN - US70975L1070 - Common Stock
PEN Key Statistics, Chart & Performance
The current stock price of PEN is 293.17 USD. In the past month the price increased by 26.62%. In the past year, price increased by 20.09%.
PEN Latest News, Press Relases and Analysis
PEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.83 | 224.14B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.61 | 203.30B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.43 | 150.59B | ||
| SYK | STRYKER CORP | 28.18 | 141.95B | ||
| IDXX | IDEXX LABORATORIES INC | 59.7 | 60.12B | ||
| BDX | BECTON DICKINSON AND CO | 13.45 | 55.61B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.72 | 50.29B | ||
| RMD | RESMED INC | 25.84 | 37.34B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.43 | 36.44B | ||
| DXCM | DEXCOM INC | 34.12 | 24.75B | ||
| PODD | INSULET CORP | 71.6 | 23.02B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 12.05 | 19.33B |
Related stock screener links
About PEN
Company Profile
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,500 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Company Info
PENUMBRA INC
One Penumbra Place
Alameda CALIFORNIA 94502 US
CEO: Adam Elsesser
Employees: 4500
Phone: 15109952486
PENUMBRA INC / PEN FAQ
What does PENUMBRA INC do?
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,500 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Can you provide the latest stock price for PENUMBRA INC?
The current stock price of PEN is 293.17 USD. The price decreased by -0.94% in the last trading session.
Does PEN stock pay dividends?
PEN does not pay a dividend.
What is the ChartMill technical and fundamental rating of PEN stock?
PEN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is PENUMBRA INC (PEN) stock traded?
PEN stock is listed on the New York Stock Exchange exchange.
What do analysts say about PENUMBRA INC (PEN) stock?
24 analysts have analysed PEN and the average price target is 319.31 USD. This implies a price increase of 8.92% is expected in the next year compared to the current price of 293.17.
What is PENUMBRA INC worth?
PENUMBRA INC (PEN) has a market capitalization of 11.48B USD. This makes PEN a Large Cap stock.
PEN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PEN. When comparing the yearly performance of all stocks, PEN is one of the better performing stocks in the market, outperforming 79.3% of all stocks.
PEN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to PEN. PEN has an excellent financial health rating, but there are some minor concerns on its profitability.
PEN Financial Highlights
Over the last trailing twelve months PEN reported a non-GAAP Earnings per Share(EPS) of 3.63. The EPS increased by 36.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.3% | ||
| ROA | 9.4% | ||
| ROE | 12.07% | ||
| Debt/Equity | 0.02 |
PEN Forecast & Estimates
24 analysts have analysed PEN and the average price target is 319.31 USD. This implies a price increase of 8.92% is expected in the next year compared to the current price of 293.17.
For the next year, analysts expect an EPS growth of 31.54% and a revenue growth 14.71% for PEN